Wu Capital logo

Wu Capital

Asia, Beijing, China, Beijing

Description

Wu Capital is a prominent venture capital and private equity firm based in Beijing, China, with a strategic focus on high-growth sectors within the Chinese market. The firm primarily targets investments in healthcare, consumer goods, high-tech (including TMT), and education, aligning with the evolving economic landscape and domestic consumption trends in China. Founded by Wu Yue, the firm has established itself as a significant player in the Chinese investment ecosystem, deploying capital across various stages of company development.

The firm's investment philosophy emphasizes long-term value creation and partnership with portfolio companies. Wu Capital manages multiple funds, including both RMB-denominated and USD-denominated vehicles, allowing for flexibility in its investment approach and catering to diverse investor bases. The firm's assets under management (AUM) are substantial, reportedly exceeding 10 billion RMB, which translates to approximately 1.4 billion USD, underscoring its capacity to make significant capital commitments. They engage in a multi-stage investment strategy, participating in rounds from early-stage ventures to more mature growth-stage and pre-IPO companies.

Wu Capital typically provides substantial financial backing to its portfolio companies. While specific first check sizes can vary depending on the stage and sector, the firm is known to make investments ranging from tens of millions to hundreds of millions of RMB. This translates to a typical first check size that can range from approximately 2.5 million USD for earlier-stage opportunities to upwards of 25 million USD for more mature, growth-oriented companies. Their strategic involvement often extends beyond capital, offering operational support and industry expertise to help accelerate the growth and market penetration of their investments.

Investor Profile

Wu Capital has backed more than 22 startups, with 1 new investments in the last 12 months alone. The firm has led 5 rounds, about 23% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in China, United States, Singapore.
  • Strong thematic focus on Health Care, Biotechnology, Apps.
  • Typical check size: $2.5M – $25M.

Stage Focus

  • Series B (32%)
  • Series C (27%)
  • Series A (27%)
  • Post Ipo Equity (5%)
  • Series E (5%)
  • Series D (5%)

Country Focus

  • China (55%)
  • United States (41%)
  • Singapore (5%)

Industry Focus

  • Health Care
  • Biotechnology
  • Apps
  • Artificial Intelligence (Ai)
  • Mobile
  • Pharmaceutical
  • Internet
  • Health Diagnostics
  • Enterprise
  • Mobile Apps
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Wu Capital frequently co-invest with?

Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 3
CA
North America, Massachusetts, United States, Boston
Co-Investments: 3
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 3
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 3
Lightspeed China Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 3
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
GGV Capital
North America, California, United States, Menlo Park
Co-Investments: 3
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 3

What are some of recent deals done by Wu Capital?

Nuvig Therapeutics

Redwood City, California, United States

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

BiotechnologyHealth CareTherapeutics
Series BDec 5, 2024
Amount Raised: $161,000,000
Ray Therapeutics

San Diego, California, United States

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

BiotechnologyHealth CareTherapeutics
Series AMay 16, 2023
Amount Raised: $100,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Series BJan 5, 2022
Amount Raised: $116,000,000
Feiliu

Shanghai, Shanghai, China

Feiliu is a provider of enterprise supply chain management and optimization technology based on artificial intelligence.

Artificial Intelligence (AI)Information TechnologyLogisticsSoftwareSupply Chain Management
Series AMay 31, 2021
Amount Raised: $31,397,174
Laiye

Beijing, Beijing, China

Laiye is an interactive platform that offers consumers and enterprises with intelligent assistant products.

AppsArtificial Intelligence (AI)EnterpriseInternetMobileMobile AppsMobile PaymentsNatural Language ProcessingRobotic Process Automation (RPA)
Series CApr 21, 2021
Amount Raised: $50,000,000
Gemini Therapeutics

Cambridge, Massachusetts, United States

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.

BiopharmaBiotechnologyHealth Diagnostics
Post Ipo EquityFeb 8, 2021
Amount Raised: $95,000,000
Medbanks

Beijing, Beijing, China

Medbanks is a database platform of clinical and professional medical services for clinical oncology.

DatabaseHealth CareHealth DiagnosticsMedicalOncology
Series EDec 21, 2020
Amount Raised: $305,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Series ASep 10, 2020
Amount Raised: $91,500,000
Citrine Medicine

Cambridge, Massachusetts, United States

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Pharmaceutical
Series AJul 13, 2020
Amount Raised: $80,000,000
Akouos

Boston, Massachusetts, United States

Akouos is a biotechnology company focusing on restoring and preserving hearing.

BiotechnologyHealth DiagnosticsPharmaceutical
Series BMar 3, 2020
Amount Raised: $105,000,000